Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma® Life Science and Axiogenesis Collaborate

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
Companies to market more predictive iPSC-based assays and services for preclinical cardiotoxicity screening.

Sigma-Aldrich® Corporation announced that Sigma Life Science, its innovative biological products and services research business, has signed an agreement with Axiogenesis to market mouse induced pluripotent stem (iPS) cell-derived cardiomyocytes and smooth muscle cells. In contrast to short-lived, tissue-derived primary cells that predominate preclinical drug discovery and cardiotoxicity screens, Sigma Life Science and Axiogenesis' iPS cell-derived primary cells enable long-term studies that are necessary to more accurately predict cardiotoxicity. These derived cell types are available as ready-to-order cells, application-specific kits and custom services catering to novice and expert users. Details are available at www.sigma.com/cardiac.

"Costly drug candidate failures in clinical trials are most frequently caused by cardiac safety issues," said John Listello, Market Segment Manager of Stem Cell Research and Regenerative Medicine at Sigma Life Science. "Early identification of these cardiac liabilities is hindered by the lack of reliable and standardized cardiomyocyte cell culture models.

"Avoiding clinical trial failures is a principle driver for the Sigma/Axiogenesis collaboration, which provides drug developers large numbers of these consistent cell culture models. This partnership deepens Sigma Life Science's commitment to alleviate critical deficiencies in ADME/Toxicology screening and preclinical development through application of iPS cell technology recently licensed from Kyoto University, CompoZr® Zinc Finger Nucleases, and the SAGEspeed(TM) Custom Animal Model Development program."

Cardiomyocytes for research and screening purposes are commonly isolated from available animal and patient tissue. The predictive utility of tissue-derived cardiomyocyte pools is limited because they do not spontaneously beat, gradually dedifferentiate into fetal-like physiological states, and contain a high percentage of contaminating cell types, such as fibroblasts that can rapidly override the culture. As a result, many critical long-term studies that could identify cardiac liabilities prior to clinical trials cannot be performed.

"In contrast, Axiogenesis' iPS cell-derived cardiomyocytes enable long-term studies that are impossible to perform in tissue-derived samples, such as accumulation studies that examine the effects of chronic dosing for several weeks at physiologically relevant, picogram levels. Accumulation patterns from such long-term studies can identify toxic compounds whose toxicity was not detectable through alternative experiments," concludes Listello.

Cardiomyocytes derived from Axiogenesis' iPS cell lines maintain physiologically-relevant biology, purity, and spontaneous beating for longer than 28 days. These iPS-cell derived cardiomyocytes are validated for functional electrophysiology, calcium-flux and calcium-wave analysis, cardiac cytotoxicity, mitochondrial metabolism, and as a disease model for cardiac hypertrophy.

Sigma Life Science's existing stem cell product portfolio includes custom iPS cell CompoZr ZFN-mediated genetic engineering, serum-free cell culture products, cell culture media, 3D matrices, growth factors, and antibodies, providing uniquely comprehensive support for iPS cell-related research. Sigma Life Science acquired a worldwide license to Kyoto University's iPS cell patent portfolio in February.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Newfound Strength in Regenerative Medicine
A promising new approach uses direct mechanical stimulation to repair severely damaged skeletal muscles.
Mapping out Cell Conversion
Researchers develop algorithm that takes the field of cell reprogramming forward.
Donor's Genotype Controls the Differentiation of IPS Cells
Pluripotent stem cells derived from different cell types are equally susceptible to reprogramming, indicates a recent study by the University of Helsinki and the National Institute for Health and Welfare, Finland. However, the genotype of the donor strongly influences the differentiation of the stem cell.
Signals That Make Early Stem Cells Identified
Researchers at The Rockefeller University have identified a new mechanism by which cells are instructed during development to become stem cells
Healing Scarred Hearts
Findings suggest stem cells may one day be used to regenerate damaged tissue after heart attack.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!